A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma (AMC-085) (NCT02298257)
This phase II trial studies the side effects and the best dose of brentuximab vedotin (also known as SGN-035) and combination chemotherapy work in treating patients with stage III-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma.
Monoclonal antibodies, including the antibody-drug conjugates or ADCs such as brentuximab vedotin, can block cancer growth by finding cancer cells and causing them to die. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.
This trial is sponsored by The Lymphoma Academic Research Organization (LYSARC) 
- Condition: Lymphoma
- Phase: I
- Estimated Enrollment: 20
- Start: May 2015
- Estimated Completion: June 2022
- Last verified: April 2015
Last Editorial review: July 11, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.